Analyst Justin Walsh from JonesTrading reiterated a Buy rating on Perspective Therapeutics and keeping the price target at $18.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Justin Walsh has given his Buy rating due to a combination of factors surrounding Perspective Therapeutics’ recent developments and potential. The company has resumed dosing patients with a 3.0 mCi level of Pb-212-VMT01, both as a monotherapy and in combination with nivolumab, after previous trials showed promising anti-tumor activity at this dosage. This decision follows the Safety Monitoring Committee’s recommendation to explore lower doses after limited activity was observed at higher doses, indicating a potential therapeutic window that could enhance the drug’s efficacy.
Furthermore, the ongoing Phase I/II trial is evaluating the clinical benefits of Pb-212-VMT01 in treating metastatic melanoma, and early data has shown encouraging results, including confirmed responses and prolonged progression-free survival. The treatment has been well-tolerated, with no dose-limiting toxicities reported, suggesting a favorable safety profile. These factors, combined with the company’s strong cash position and innovative technology, support the Buy rating and the $18 price target set by Walsh.
According to TipRanks, Walsh is a 3-star analyst with an average return of 3.5% and a 36.60% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Beyond Air, and Achieve Life Sciences.
In another report released today, Oppenheimer also reiterated a Buy rating on the stock with a $14.00 price target.